Agios Pharmaceuticals, Inc. (AGIO) stock

AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302% below fair value

$31.59−0.17 (-0.54%)

Close on Nov 13, 2026Market cap $1.89BP/E –Yield –

Agios Pharmaceuticals EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Agios Pharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Agios Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AGIO.

Revenue growth214.4% · median 29.9%

Gross margin93.8% · median 84.3%

Operating margin-297.7% · median 26.3%

Net margin-264.8% · median 35.3%

Advertisement
300 × 250

See a number that looks wrong?